These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 11162590

  • 1. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells.
    Sun SY, Yue P, Zhou JY, Wang Y, Choi Kim HR, Lotan R, Wu GS.
    Biochem Biophys Res Commun; 2001 Jan 26; 280(3):788-97. PubMed ID: 11162590
    [Abstract] [Full Text] [Related]

  • 2. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
    Sun SY, Yue P, Hong WK, Lotan R.
    Cancer Res; 2000 Dec 15; 60(24):7149-55. PubMed ID: 11156424
    [Abstract] [Full Text] [Related]

  • 3. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
    Ozören N, El-Deiry WS.
    Neoplasia; 2002 Dec 15; 4(6):551-7. PubMed ID: 12407450
    [Abstract] [Full Text] [Related]

  • 4. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K, Douglas L, Delaney A, Houghton JA.
    Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455
    [Abstract] [Full Text] [Related]

  • 5. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
    Walczak H, Bouchon A, Stahl H, Krammer PH.
    Cancer Res; 2000 Jun 01; 60(11):3051-7. PubMed ID: 10850456
    [Abstract] [Full Text] [Related]

  • 6. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
    Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, Srivastava RK.
    Cancer Res; 2003 Apr 01; 63(7):1712-21. PubMed ID: 12670926
    [Abstract] [Full Text] [Related]

  • 7. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
    Suliman A, Lam A, Datta R, Srivastava RK.
    Oncogene; 2001 Apr 19; 20(17):2122-33. PubMed ID: 11360196
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.
    Fulda S, Meyer E, Debatin KM.
    Oncogene; 2002 Apr 04; 21(15):2283-94. PubMed ID: 11948412
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
    Röhn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, Weller M.
    Oncogene; 2001 Jul 12; 20(31):4128-37. PubMed ID: 11464279
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 17. Synergistic inhibition of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human pancreatic beta cells by Bcl-2 and X-linked inhibitor of apoptosis.
    Ou D, Wang X, Metzger DL, James RF, Pozzilli P, Plesner A, Korneluk RG, Verchere CB, Tingle AJ.
    Hum Immunol; 2005 Mar 01; 66(3):274-84. PubMed ID: 15784465
    [Abstract] [Full Text] [Related]

  • 18. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines.
    Chawla-Sarkar M, Leaman DW, Borden EC.
    Clin Cancer Res; 2001 Jun 01; 7(6):1821-31. PubMed ID: 11410525
    [Abstract] [Full Text] [Related]

  • 19. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M.
    Oncogene; 2006 Dec 07; 25(58):7618-34. PubMed ID: 16983347
    [Abstract] [Full Text] [Related]

  • 20. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
    Munshi A, Pappas G, Honda T, McDonnell TJ, Younes A, Li Y, Meyn RE.
    Oncogene; 2001 Jun 28; 20(29):3757-65. PubMed ID: 11439339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.